预约演示

Bristol Myers Squibb acquires RayzeBio for $4.1bn

2024-02-27

临床1期临床3期并购

Through the RayzeBio acquisition, BMS will gain access to an RPT manufacturing facility. Credit: JHVEPhoto / Shutterstock.com.

Bristol MyerRayzeBio (BMS) has annBMSced the conclusion of its acquisition of RayzeBio, a clinical-stage radiopharmaceutical company, for $4.1bn.

Bristol Myers Squibbolly owned BMS subsidiary.RayzeBio

RayzeBioanies signed an agreemeBMSfor the acquisition in December 2023 in which BMS would acquire all outstanding shares of RayzeBio.

The acquisition introduces a radiopharmaceutical therapeutics (RPTs) pipeline toBMSS, including the lead programme, RYZ101 (RayzeBioTATATE). This therapy is designed to target somatostatin receptor (SSTR)2, which is overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and extensive stage small cell lung cancer (ES-SCLC).

A Phase III clinical trial is currently enrolling subjects to assess RYZ101 in individuals with SSTR-positive GEP-NERYZ101 h²²⁵Ac-DOTATATE received treatment with lutetium-177-based somatostatin therapies.gastroenteropancreatic neuroendocrine tumours (GEP-NETs)small cell lung cancer (ES-SCLC)

See Also:CC-98633 by Bristol-Myers Squibb for Refractory Multiple MyeRYZ101Likelihood of ApprovaSSTR-positive GEP-NETs SSTR lutetium-177-based

CC-98633 CC-98633ol-MBristol-Myers Squibbpsed Refractory Multiple Myelomad of Approval

Interim data from the Phase Ib portion of the ACTION-1 clinical trial for RYZ101 have shown encouraging tolerability and efficacy.

CC-98633Ib tBristol-Myers Squibbsing Relapsed Multiple Myelomast-line treatment for ES-SCLC in combination with standard-of-care therapy.

The acquisition also includes an RPT manufacturing facility which will commence operations in the first half of 2024.

BMS CEO Chris Boerner stated: “We are excited to complete this transactionRYZ101h adds RPTs, one of the fastest-growing new modalities for treating patients with solid tumours.

“By strengthening and further diversifying our RYZ101gy pipeline beyond I-O, we willES-SCLC exciting opportunities that support BMS’s growth in the back half of the decade and beyond. RayzeBio is a pioneer in the application of this novel modality, and we look forward to working with their talented team to accelerate their preclinical and clinical programmes for the benefit of patients around the world.”

The latest deal comes after BMS entered a $674m collaboration with US deep tech company VantAI.

BMS partnership will focus on using VantAI’s generative AI platform to design and develop molecular glues – a small molecule that induces or stabilises interactiosolid tumourso proteins that would not normally go together.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构